About five months after U.S. Department of Health and Human Services Secretary Robert F. Kennedy Jr. touted leucovorin as “an exciting therapy that may benefit large numbers of children who suffer ...

Monday’s FDA approval makes Filspari the first therapy specifically indicated for FSGS, a condition that represents a $1 ...

A BridgeBio Pharma drug developed for dwarfism increased children’s growth rates in a pivotal clinical trial, meeting the study’s main goal and boosting the daily pill’s chances to offer an ...

Ascletis Pharma has received investigational new drug (IND) clearance from the US Food and Drug Administration (FDA) to begin a 13-week Phase II study of its oral small molecule glucagon-like peptide ...

SHINKEI THERAPEUTICS RECEIVES FDA CLEARANCE TO PROCEED WITH PHASE 1 CLINICAL TRIAL FOR MR-101 AND COMPLETES PHASE 2 CLINICAL TRIAL FOR MR-301 IN SEVERE TBI PRINCETON ...

A Rocket Pharmaceuticals gene therapy has landed a long-awaited FDA approval, bringing a new treatment option to patients with a certain inherited immunodeficiency so severe that many babies do not ...

POTOMAC, MD / ACCESS Newswire / January 22, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage pharmaceutical company leveraging Artificial Intelligence ("AI") to ...

Add Yahoo as a preferred source to see more of our stories on Google. Tanabe Pharma is one of two companies developing a treatment for EPP and XLP. Image credit: Guenter Albers / Shutterstock.com ...

GlycoNex expects to enrol patients in Japan and submit an IND in Taiwan by June 2026.